These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20730068)

  • 1. Dronedarone for the treatment of atrial fibrillation and atrial flutter: approval and efficacy.
    Wolbrette D; Gonzalez M; Samii S; Banchs J; Penny-Peterson E; Naccarelli G
    Vasc Health Risk Manag; 2010 Aug; 6():517-23. PubMed ID: 20730068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Gonzalez MD
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):24S-30S. PubMed ID: 21098416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dronedarone for the treatment of atrial fibrillation and atrial flutter.
    Maund E; McKenna C; Sarowar M; Fox D; Stevenson M; Pepper C; Palmer S; Woolacott N
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):55-62. PubMed ID: 21047492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-ATHENA and beyond.
    Naccarelli GV
    J Interv Card Electrophysiol; 2011 Jun; 31(1):55-60. PubMed ID: 21336617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter.
    Dale KM; White CM
    Ann Pharmacother; 2007 Apr; 41(4):599-605. PubMed ID: 17389667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dronedarone in the treatment of atrial fibrillation/flutter in the aftermath of PALLAS.
    Naccarelli GV; Kowey PR
    Curr Cardiol Rev; 2014 Nov; 10(4):303-8. PubMed ID: 24821656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.
    Naccarelli GV; Johnston SS; Lin J; Patel PP; Schulman KL
    Clin Cardiol; 2010 May; 33(5):270-9. PubMed ID: 20513065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
    Singh BN; Connolly SJ; Crijns HJ; Roy D; Kowey PR; Capucci A; Radzik D; Aliot EM; Hohnloser SH;
    N Engl J Med; 2007 Sep; 357(10):987-99. PubMed ID: 17804843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL; Connolly SJ; Crijns HJ; van Eickels M; Gaudin C; Torp-Pedersen C; Hohnloser SH;
    Am J Cardiol; 2011 Apr; 107(7):1019-22. PubMed ID: 21296333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dronedarone.
    Patel C; Yan GX; Kowey PR
    Circulation; 2009 Aug; 120(7):636-44. PubMed ID: 19687370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
    Duray GZ; Schmitt J; Hohnloser SH
    J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4 Suppl):19S-23S. PubMed ID: 20472812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial.
    Reynolds MR; Lin J; Jhaveri M; Mozaffari E; Plich A
    Am J Ther; 2014; 21(6):500-8. PubMed ID: 23344106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic profile of dronedarone , a new antiarrhythmic agent for the treatment of atrial fibrillation.
    Rosa GM; Bianco D; Parodi A; Valbusa A; Zawaideh C; Bizzarri N; Ferrero S; Brunelli C
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1751-64. PubMed ID: 25349898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dronedarone: a review of randomized trials.
    Christiansen CB; Torp-Pedersen C; Køber L
    Expert Opin Drug Saf; 2010 Jan; 9(1):189-99. PubMed ID: 20001756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation.
    Schweizer PA; Becker R; Katus HA; Thomas D
    Drug Des Devel Ther; 2011 Jan; 5():27-39. PubMed ID: 21267357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dronedarone: a promising alternative for the management of atrial fibrillation.
    Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.
    Garcia D; Cheng-Lai A
    Cardiol Rev; 2009; 17(5):230-4. PubMed ID: 19690474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dronedarone in atrial fibrillation and flutter on stroke reduction.
    Christiansen CB; Torp-Pedersen C; Køber L
    Clin Interv Aging; 2010 Apr; 5():63-9. PubMed ID: 20396635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dronedarone for atrial fibrillation: a new therapeutic agent.
    Patel PD; Bhuriya R; Patel DD; Arora BL; Singh PP; Arora RR
    Vasc Health Risk Manag; 2009; 5():635-42. PubMed ID: 19688104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.